Latest news

• Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

  First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in

• Regeneron's bispecific for lymphoma works in CAR-T failures

  Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies. ... rates in patients with relapsed or refractory diffuse

• FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

  R. 2. has the potential to offer patients with previously treated follicular lymphoma and marginal zone lymphoma a chemotherapy free option”, said Jay Backstrom, chief medical officer and Head of Global ... These results wildly contrasted to a previous

• Regeneron’s early stage bispecific shows promise

  refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), the two most common types of Non-Hodgkins Lymphoma (NHL). ... refractory follicular lymphoma patients," said Israel Lowy, M.D., Ph.D., Head of Clinical and Translational

• Celgene’s Revlimid gets a win in late-stage lymphoma

  The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s established lymphoma therapy Rituxan (rituximab) in patient with two types of NHL – follicular lymphoma (FL) and marginal zone lymphoma (MZL) – and showed ... An earlier read-out in